经导管主动脉瓣植入术后非心脏手术的风险与时机
这项来自瑞士伯尔尼大学医院前瞻性TAVI注册表的队列研究纳入2238例TAVI患者中300例后续接受非心脏手术者(择期160例、紧急140例),评估术后30天内死亡、卒中、心肌梗死和大出血的复合终点。63例(21.0%)在TAVI后30天内手术。30天复合终点发生于58例,Kaplan-Meier估计19.7%(95%CI 15.6%-24.7%)。手术时机(TAVI至非心脏手术≤30天)、紧急程度和风险类别与终点风险增加无关;中度或重度瓣膜-患者不匹配(aHR 2.33;95%CI 1.37-3.95;P=.002)和中度或重度瓣周反流(aHR 3.61;95%CI 1.25-10.41;P=.02)与终点风险增加独立相关。作者认为非心脏手术可在成功TAVI后早期进行,但装置性能欠佳与不良结局风险增加相关。
要点
- 300例TAVI后非心脏手术患者中,30天复合终点(死亡、卒中、心肌梗死、大出血或危及生命出血)Kaplan-Meier估计19.7%(95%CI 15.6%-24.7%)。
- 63例(21.0%)在TAVI后30天内接受非心脏手术,手术时机(≤30天)、紧急程度和风险类别与终点风险增加无关。
- 中度或重度瓣膜-患者不匹配与30天复合终点风险增加独立相关(aHR 2.33;95%CI 1.37-3.95;P=.002)。
- 中度或重度瓣周反流与30天复合终点风险增加独立相关(aHR 3.61;95%CI 1.25-10.41;P=.02)。
- 作者认为非心脏手术可在成功TAVI后早期进行;装置性能欠佳与不良结局风险增加相关。
适用人群与场景
- 2013年至2020年在瑞士伯尔尼大学医院(三级医疗中心)前瞻性TAVI注册表中接受TAVI、随后接受非心脏手术的患者。
- 共300例,平均(SD)年龄81.8(6.6)岁,144例(48.0%)女性;择期手术160例,紧急手术140例。
研究设计与关键结果
- 研究类型:基于前瞻性TAVI注册表的队列研究;共2238例TAVI患者,其中300例接受非心脏手术并纳入分析。
- 手术风险类别:低风险21例、中风险190例、高风险89例;63例(21.0%)在TAVI后30天内手术。
- 主要终点:术后30天内死亡、卒中、心肌梗死、大出血或危及生命出血的复合终点,58例发生,Kaplan-Meier估计19.7%(95%CI 15.6%-24.7%)。
- 有无30天复合终点患者的基线人口学无显著差异:平均(SD)年龄81.3(7.1)岁 vs 81.9(6.5)岁(P=.28);女性25例(43.1%) vs 119例(49.2%)(P=.37)。
- 手术时机(TAVI至非心脏手术≤30天)、紧急程度和手术风险类别与终点风险增加无关。
- 中度或重度瓣膜-患者不匹配与终点风险增加独立相关(aHR 2.33;95%CI 1.37-3.95;P=.002)。
- 中度或重度瓣周反流与终点风险增加独立相关(aHR 3.61;95%CI 1.25-10.41;P=.02)。
证据类型、等级与局限
- 证据类型:基于前瞻性注册表的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,非心脏手术可在成功TAVI后早期进行。
- 作者指出,装置性能欠佳(如瓣膜-患者不匹配和瓣周反流)与TAVI后非心脏手术不良结局风险增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Noncardiac surgery after transcatheter aortic valve implantation (TAVI) is a clinical challenge with concerns about safety and optimal management.
OBJECTIVES: To evaluate perioperative risk of adverse events associated with noncardiac surgery after TAVI by timing of surgery, type of surgery, and TAVI valve performance.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted using data from a prospective TAVI registry of patients at the tertiary care University Hospital in Bern, Switzerland. All patients undergoing noncardiac surgery after TAVI were identified. Data were analyzed from November through December 2021.
EXPOSURES: Timing, clinical urgency, and risk category of noncardiac surgery were assessed among patients who had undergone TAVI and subsequent noncardiac surgery.
MAIN OUTCOMES AND MEASURES: A composite of death, stroke, myocardial infarction, and major or life-threatening bleeding within 30 days after noncardiac surgery.
RESULTS: Among 2238 patients undergoing TAVI between 2013 and 2020, 300 patients (mean [SD] age, 81.8 [6.6] years; 144 [48.0%] women) underwent elective (160 patients) or urgent (140 patients) noncardiac surgery after TAVI and were included in the analysis. Of these individuals, 63 patients (21.0%) had noncardiac surgery within 30 days of TAVI. Procedures were categorized into low-risk (21 patients), intermediate-risk (190 patients), and high-risk (89 patients) surgery. Composite end points occurred within 30 days of surgery among 58 patients (Kaplan-Meier estimate, 19.7%; 95% CI, 15.6%-24.7%). There were no significant differences in baseline demographics between patients with the 30-day composite end point and 242 patients without this end point, including mean (SD) age (81.3 [7.1] years vs 81.9 [6.5] years; P = .28) and sex (25 [43.1%] women vs 119 [49.2%] women; P = .37). Timing (ie, ≤30 days from TAVI to noncardiac surgery), urgency, and risk category of surgery were not associated with increased risk of the end point. Moderate or severe prosthesis-patient mismatch (adjusted hazard ratio [aHR], 2.33; 95% CI, 1.37-3.95; P = .002) and moderate or severe paravalvular regurgitation (aHR, 3.61; 95% CI 1.25-10.41; P = .02) were independently associated with increased risk of the end point.
CONCLUSIONS AND RELEVANCE: These findings suggest that noncardiac surgery may be performed early after successful TAVI. Suboptimal device performance, such as prosthesis-patient mismatch and paravalvular regurgitation, was associated with increased risk of adverse outcomes after noncardiac surgery.
参考来源
- Okuno T, Demirel C, Tomii D, et al. Risk and Timing of Noncardiac Surgery After Transcatheter Aortic Valve Implantation. JAMA Netw Open. 2022. PMID: 35797045. doi:10.1001/jamanetworkopen.2022.20689
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。